WHO Issues Concern Over Acute Lack of Obesity Injections
Fewer than one in 10 people who could benefit from weight-loss injections like Wegovy are able to get them, states the World Health Organization as it publishes its first recommendations on the therapies.
With more than one billion people worldwide now classified as obese, it is urging increased and just availability to GLP-1 medication.
Based on estimates, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"The new guidelines recognises that obesity is a lifelong illness that can be treated with thorough and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are key barriers to widespread access to the treatments that can assist patients in reducing considerable body mass, says the body.
Skinny Jab Supply Crisis
Even under the present best projected case, the manufacturing of GLP-1 therapies might only reach around 100 million people – less than 10% of the global need, per the health organization.
The guideline calls on nations and manufacturers to increase availability, through measures including patent sharing.
A patent on the active ingredient – the main ingredient of a leading brand – is scheduled to end in several nations in 2026.
The Way Obesity Jabs Function
These medications replicate a body's own hormone to reduce digestion speed, curb appetite and increase satiety so people reduce food intake.
Individuals typically start to lose weight within a few weeks of beginning the weekly injections.
Evidence points to patients may put most of the weight back on after a year of halting the treatment, when their normal appetite resume.
To be carrying excess weight elevates your risk for experiencing health problems, like type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight affects individuals in all nations and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
